Drugs / OPL-0401
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05393284 | Aug 2022 → Aug 2024 | proliferative diabetic retinopathy | Valo Health, Inc. | Unknown | Missed primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-12-31 | Valo Health, Inc. | Results Valo Health Announces Topline Results from Phase 2 SPECTRA Study of OPL-0401 in Patients with Diabetic Retinopathy valohealth.com ↗
While the study did not meet its primary or secondary endpoints based on the analysis in the predefined primary population, certain doses tested in the study showed potential evidence of preventing disease progression. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-12-31 | Valo Health, Inc. | Valo Health Announces Topline Results from Phase 2 SPECTRA Study of OPL-0401 in Patients with Diabetic Retinopathy valohealth.com ↗ |
| 2024-03-04 | Valo Health, Inc. | Valo Health Completes Enrollment of OPL-0401 Phase 2 Study for the Treatment of Diabetic Retinopathy valohealth.com ↗ |
| 2022-08-18 | Valo Health, Inc. | Valo Announces First Patient Dosed in the OPL-0401 Phase 2 study of an oral ROCK1/2 inhibitor for the Treatment of Non-Proliferative Diabetic Retinopathy valohealth.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OPL-0401 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05393284 ↗ |
| Route | Oral | “Route of Administration: Oral” NCT05393284 ↗ |